PARP1 and glioblastoma: Administering olaparib PARP (poly (ADP-ribose) polymerase) inhibitor, developed for BRCA1/2 mutated ovarian cancer, in combination with TMZ has shown promising results for treating relapsed glioblastoma patients in a phase I clinical trial (NCT01390571) [44].